Duvyzat is recommended within the EU for approval as DMD treatment, as Lila Levinson reports. The drug itself was recently approved by an arm of the European Medicines Agency, Committee for Medicinal Products for Human Use, for Duchenne muscular dystrophy. Genetic mutations are the cause behind muscular dystrophy in which the progressive disease weakens the muscles and leads to various symptoms such as difficulty in movement or trouble breathing. Duchenne muscular dystrophy is named after mutations in the DMD gene and is the most common form of muscular dystrophy. Duvyzat blocks particular enzymes which help regulate certain genetic activity of cells, in addition to lowering inflammation, ease scarring and fat infiltration of muscles. Follow Lila Levinson as they write about this promising drug that may help patients with muscular dystrophy.
Photo: Duchenne, Guillaume-Benjamin via Wikimedia Commons
